HIV/AIDS and Infections
15
2
2
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (15)
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Black Men Ages 14-19 Attracted to Men
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya
POSSE Project: A Community-Level Intervention for Black YMSM
Antiretroviral Regime for Viral Eradication in Newborns
Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention
Patient-Reported Outcomes HIV BItherapy
Evaluation of Clinical Impacts and Costs of eHealth in Rwanda
A Community-University Approach to Preventing HIV
Puerto Rico Cuidalos Parent-adolescent Program
Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan
Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda
Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department